Back to News
Market Impact: 0.25
Oncolytics Biotech® Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven Cancers
Source: globenewswire.com
Healthcare & BiotechCompany Fundamentals
Oncolytics reported durability and survival data in anal cancer from the GOBLET study: 100% of responding patients survived longer than one year. The article provides no patient count, comparator, or further study details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment
ONCY0.70
More News
- SK Hynix Posts Record Profit Amid AI Rush
- SK Hynix third-quarter profit sharply beats estimates on AI memory boost
- Anthropic's IPO could be 'speculative fiction' or a 'generational moment' — investors are split
- Anthropic Gives Traders a Pure-Play Bet on Frontier AI
- Analysis-Hold or sell? High Treasury yields spur US banks to rethink bond portfolios
- VCs will make billions on Anthropic’s IPO, but Amazon is set to make much (much) more